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Abstract Serum urate, the final breakdown product of
purine metabolism, is causally involved in the pathogenesis
of gout, and implicated in cardiovascular disease and type
2 diabetes. Serum urate levels highly differ between men
and women; however the underlying biological processes
in its regulation are still not completely understood and are
assumed to result from a complex interplay between
genetic, environmental and lifestyle factors. In order to
describe the metabolic vicinity of serum urate, we analyzed
355 metabolites in 1,764 individuals of the population-
based KORA F4 study and constructed a metabolite net-
work around serum urate using Gaussian Graphical Mod-
eling in a hypothesis-free approach. We subsequently
investigated the effect of sex and urate lowering
medication on all 38 metabolites assigned to the network.
Within the resulting network three main clusters could be
detected around urate, including the well-known pathway
of purine metabolism, as well as several dipeptides, a group
of essential amino acids, and a group of steroids. Of the 38
assigned metabolites, 25 showed strong differences
between sexes. Association with uricostatic medication
intake was not only confined to purine metabolism but seen
for seven metabolites within the network. Our findings
highlight pathways that are important in the regulation of
serum urate and suggest that dipeptides, amino acids, and
steroid hormones are playing a role in its regulation. The
findings might have an impact on the development of
specific targets in the treatment and prevention of
hyperuricemia.
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1 Introduction
Since the early 1800s, hyperuricemia is known to be causally
involved in the pathogenesis of gout, a painful inflammatory
arthritis induced by the deposition of monosodium urate
crystals in synovial fluid and other tissues (Kanbay et al.
2011; Neogi 2011). Increased serum urate concentrations
are implicated in cardiovascular disease and elevated urate is
associated with obesity, hypertension and insulin resistance,
and consequently with the metabolic syndrome and type 2
diabetes (Hayden and Tyagi 2004; Koenig and Meisinger
2008). By contrast, the relatively high serum urate levels of
humans compared to most other mammals are believed to
play a positive role as an antioxidant (Wu et al. 2011). Thus,
human physiology is especially sensitive to the precise range
of serum urate levels.
In humans and higher primates, who have lost hepatic
uricase activity during evolution, serum urate is the final
oxidation product of purine metabolism. Serum urate is
produced by xanthine oxidase from xanthine and hypo-
xanthine and is excreted in urine by the proximal tubular
cells of the kidney. The regulation of serum urate con-
centrations is regarded as a result of complex interplays
between genetic, lifestyle, and environmental factors.
Recently, genome-wide association studies (GWAS) have
identified single nucleotide polymorphisms (SNPs) asso-
ciated with serum urate concentrations and gout, several of
them located in genes coding for renal transport proteins
(Doring et al. 2008; Kolz et al. 2009; Kottgen et al. 2013;
Li et al. 2007; Vitart et al. 2008; Wallace et al. 2008; Yang
et al. 2010). However, despite the success of these GWAS,
detailed functional information on the underlying biologi-
cal processes is still lacking.
Metabolomics, the study of ideally all metabolites in a
biological system, is one of the youngest of the ‘‘omics’’
sciences. Metabolites are the end products of cellular reg-
ulatory processes and may provide more details on poten-
tially affected biological pathways (Ma et al. 2012). The
detection and functional characterization of such pathways
is crucial to improve management and treatment of patients
with hyperuricemia and gout.
In order to investigate the metabolic vicinity of serum
urate, we performed metabolite profiling of 1,764 indi-
viduals of the KORA F4 survey and examined serum urate
connected metabolites using Gaussian Graphical Models
(GGMs). In previous studies, we have demonstrated these
statistical models to reconstruct metabolic pathways from
large-scale metabolomics data (Krumsiek et al. 2011). To
address the pronounced sex differences in the regulation of
serum urate concentrations we analyzed sex differences
within the network. Additionally, we analyzed the influ-
ence of urate lowering medication for all metabolites
within the generated network.
2 Materials and methods
2.1 Study population
The KORA studies (Cooperative Health Research in the
Region of Augsburg) is a series of independent population
based studies from the general population living in the
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region of Augsburg, southern Germany (Holle et al. 2005;
Wichmann et al. 2005). The KORA S4 survey, was con-
ducted in 1999–2001 including 4,261 participants
(response 67 %). A total of 3,080 subjects participated in
the follow-up examination KORA F4 in 2006–2008. The
present analysis comprises 1,764 KORA F4 participants
(908 females and 856 males) in an age range of
32–81 years (mean 60.86 years). Of those, 83 participants
were treated by urate lowering medication (17 females and
66 males). All 83 were treated by allopurinol (uricostatic
drug) and four of them additionally by benzbromaron
(uricosuric drug). Written informed consent has been given
by all participants and the study has been approved by the
Ethics Committee of the Bavarian Medical Association.
2.2 Blood sampling
Blood samples were collected as part of the KORA F4
follow-up. To avoid variation due to circadian rhythm,
blood was drawn in the morning between 08:00 and 10:30
after a period of at least 10 h overnight fasting. Material
was drawn into serum gel tubes, gently inverted twice and
then allowed to rest for 30 min at room temperature
(18–25 C) to obtain complete coagulation. The material
was then centrifuged for 10 min (2,750 g at 15 C). Serum
was divided into aliquots and kept for a maximum of 6 h at
4 C, after which it was frozen at -80 C until analysis.
2.3 Metabolomics measurements
Metabolites were measured in 1,768 subjects from the
KORA F4 study by Metabolon, Inc. (Durham, NC, USA), a
commercial supplier of metabolic analyses, who has
developed a platform that integrates the chemical analysis,
including identification and relative quantification, data-
reduction and quality-assurance using three separate ana-
lytical methods (GC–MS, LC–MS (positive mode), LC–
MS (negative mode)) to detect as wide a range of metab-
olites as possible (Evans et al. 2009; Suhre et al. 2011).
Sample preparation was assisted by a Hamilton ML
STAR (Hamilton Company, Salt Lake City, UT, USA)
robotics system. After thawing, 400 ll of extraction sol-
vent (i.e. methanol, containing recovery standards) was
added to each 100 ll of serum samples in a 96 deep well
plate format. Extraction was carried out by shaking for
2 min using a Geno/Grinder 2000 (Glen Mills Inc., Clifton,
NJ, USA). After centrifugation the supernatant was split
into four aliquots: two for LC/MS analysis (positive and
negative electrospray ionization mode), one for GC/MS
analysis and one reserve aliquot. Solvent was removed on a
TurboVap (Zymark) and the samples were dried under
vacuum overnight. For LC/MS pos. ion mode samples were
reconstituted with 0.1 % formic acid, for neg. ion mode
with 6.5 mM ammonium bicarbonate pH 8.0. Both recon-
stitution solvents contained also internal standards. The
GC/MS aliquots were derivatized for 1 h at 60 C with
N,O-bistrimethylsilyl-trifluoroacetamide in a solvent mix-
ture of acetonitrile:dichlormethane:cyclohexane (5:4:1),
containing 5 % triethylamine and retention time markers.
LC/MS analysis was performed on a LTQ mass spec-
trometer (Thermo Fisher Scientific Inc., Waltham, MA,
USA) equipped with a Waters Acquity UPLC system
(Waters Corporation, Milford, MA, USA). Two separate
columns (2.1 9 100 mm Waters BEH C18 1.7 lm parti-
cle) were used for acidic (solvent A: 0.1 % formic acid in
H2O, solvent B: 0.1 % formic acid in methanol) and basic
(A: 6.5 mM ammonium bicarbonate pH 8.0, B: 6.5 mM
ammonium bicarbonate in 98 % methanol) mobile phase
conditions, optimized for positive and negative electro-
spray ionization, respectively. After injection of the sample
extracts the columns were developed in a gradient of
100 % A to 98 % B in 11 min runtime at 350 ll/min flow
rate. The eluent flow was directly connected to the ESI
source of the LTQ mass spectrometer. Full scan mass
spectra (99–1000 m/z) and data dependent MS/MS scans
with dynamic exclusion were recorded in turns.
GC/MS analysis was done on a Thermo-Finnigan Trace
DSQ fast-scanning single-quadrupole mass spectrometer,
equipped with a 20 m 9 0.18 mm GC column with
0.18 lm film phase consisting of 5 % phenyldimethyl sil-
icone. Electron impact ionization at 70 eV was used and
the column temperature was ramped between 60 and
340 C with helium as carrier gas. Mass spectra in a scan
range from 50 to 750 m/z, were recorded.
Metabolites were identified from the LC/MS and GC/
MS data by automated multiparametric comparison with a
proprietary library, containing retention times, m/z ratios,
and related adduct/fragment spectra for over 1,500 standard
compounds measured by Metabolon. For each identified
metabolite the raw area counts were normalized to the
median value of the run day to correct for inter-day vari-
ation of the measurements.
The panel includes 517 untargeted metabolites, spanning
several metabolic classes (amino acids, acylcarnitines,
sphingomyelins, glycerophospholipids, carbohydrates, vita-
mins, lipids, nucleotides, peptides, xenobiotics and steroids).
The quantified metabolites can be distinguished into chemi-
cally identified metabolites, and unidentified, here called
‘‘unknown’’ metabolites. Nine of those unknown metabolites
have recently been identified by Krumsiek et al. (2012). Urate
is one of the measured metabolites on the panel.
From the original data matrix containing 1,768 samples
and 517 metabolites, we first excluded metabolites with
more than 20 % missing values and then samples with more
than 10 % missing values. The filtered data matrix contained
n = 1,764 samples and 355 metabolites (241 known and
New insights into the regulation of serum urate in humans 143
123
114 unknown). All normalized ion counts were transformed
by natural logarithm and missing values were imputed using
the ‘mice’ R package (van Buuren and Groothuis-Oudsho-
orn 2011). Detailed information about all analyzed metab-
olites is provided in Supplementary Table 1.
2.4 Identification of the unknown metabolite X-11422
Within the generated GGM xanthine was not directly
connected to urate and hypoxanthine but via the unknown
metabolite X-11422 (see Supplementary Fig. 1). The cen-
tral position of X-11422 in this well-known pathway
induced speculations about its chemical identity. Following
the ideas for unknown identification in Krumsiek et al.
(2012), we defined possible candidates by considering the
direct neighbors of X-11422 in the GGM, its mass, and its
fragmentation spectrum: alloxanthine, the primary metab-
olite of allopurinol, or xanthine itself displaying altered
chromatographic characteristics. Xanthine was originally
measured and identified on two out of the three analytical
methods used to profile metabolites. Interestingly, xanthine
was not detected on the third platform; rather X-11422 was
detected. In order to determine if the unknown could be
either one of these candidates, we performed a co-elution
spiking experiment. We spiked several candidate mole-
cules, including xanthine and alloxanthine, that had the
same molecular formula (as determined by accurate mass
spectrometric analysis using an Orbitrap Elite mass spec-
trometer operated at 30,000 resolution) and fragmentation
spectrum when run neat, into both urate medication treated
and non-treated patient samples. Specifically, treated and
non-treated medication samples were run with no spike,
low, medium, and high spikes of both xanthine and allo-
xanthine separately, as well as spiked with both molecules
simultaneously, to determine if either candidate co-eluted
with the peak identified as X-11422. Positive confirmation
of identity of X-11422, given the candidates already dis-
played identical molecular formula and fragmentation
spectrum, would show an exact co-elution of the candidate
molecules with the unknown in the treated samples.
This experiment demonstrated that xanthine, not allo-
xanthine, co-eluted perfectly in this matrix with the peak
identified as X-11422 and therefore X-11422 represented an
alternate measurement of xanthine. The original measure-
ment of xanthine and the alternate measurement of xanthine
(X-11422) correlate with a Pearson Correlation of r = 0.60
and show highly similar response to treatment. It is inter-
esting to note that the alternate measurement of xanthine
showed an increased correlation to the treatment as opposed
to the original measurement. Since these two measurements
are occurring on two different analytical methods with dif-
ferent background and chemical noise characteristics, slight
differences in relative quantitation is not surprising.
2.5 Medication ascertainment
All participants were asked to bring to the interview all
medications taken in the 7 days preceding the examination.
Medication data was obtained online using the IDOM
program (online drug-database leaded medication assess-
ment). The medications were categorized according to the
Anatomical Therapeutical Chemical (ATC) classification
index.
2.6 Statistical analysis
Within the original data matrix of 355 metabolites, partial
correlations were calculated between each metabolite pair
conditioning on age, sex, all other metabolites as well as
SNPs which showed a significant association with at least
one of the 355 known or unknown metabolites as described
before (Krumsiek et al. 2012). Correlations between two
metabolites were considered to be significant at a signifi-
cance level of 0.05 and a correction for multiple testing by
the false discovery rate (FDR) (Benjamini and Hochberg
1995; Benjamini and Yekutieli 2001). Significant partial
correlations were visualized in a network graph, referred to
a Gaussian graphical model (GGM). In previous studies,
we have demonstrated that GGMs are able to reconstruct
metabolic pathways from large-scale metabolomics data
(Krumsiek et al. 2012, 2011). Within the GGM each node
presents a metabolite and nodes are connected by an edge if
their partial correlation is significant. Here, we visualize
the network in a 3-neighborhood around urate, which
means that all metabolites are assigned to the network
graph if they are connected to urate by three or less edges.
The initially generated network is visualized in Sup-
plementary Fig. 1. As the unknown metabolite X-11422
was located at a central position within the known purine
pathway, we investigated on its identification as described
above and identified it to be an alternate measurement of
xanthine. In order to avoid duplicated metabolites within
the graph, we removed known duplicates from the data-
matrix and regenerated the GGM in the remaining 353
metabolites. The FDR corrected significance level of 0.05
involved a p value cutoff of 4.34 9 10-5. All metabolites
within the network were tested for their associations with
sex and urate lowering medication using a linear model
which was additionally adjusted for age. Effects were
considered to be significant below a threshold of
6.6 9 10-4, which corresponds to a Bonferroni correction
for 76 independent tests.
Furthermore, we tested all pairwise partial correlations
within the set of 353 metabolites for sex differences. Partial
correlation coefficients were calculated separately in males
and females. In contrary to the overall coefficients, we did
not adjust for the set of SNPs in order to ensure a reliable
144 E. Albrecht et al.
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Table 1 Partial correlation
coefficients for all significant
associations within a
3-neighborhood of serum urate
Metabolite 1 Metabolite 2 Partial correlation
coefficient
p value
Urate Histidine -0.231 9.08E-13
Urate Methionine 0.181 2.54E-08
Urate N-[3-(2-oxopyrrolidin-1-yl)
propyl]acetamide
0.142 1.37E-05
Urate Androstene disulfate 0.153 2.52E-06
Urate Xanthine -0.277 5.27E-18
Histidine Methionine 0.188 7.06E-09
Methionine Tyrosine 0.142 1.32E-05
Androstene disulfate Dehydroepiandrosterone sulfate 0.351 1.40E-28
Androstene disulfate Epiandrosterone sulfate -0.176 5.38E-08
Androstene disulfate X-18601 0.146 7.54E-06
Androstene disulfate X-11440 0.352 1.13E-28
Androstene disulfate X-11443 0.510 3.16E-63
Androstene disulfate X-11450 0.156 1.60E-06
Xanthine Aspartylphenylalanine 0.147 6.10E-06
Xanthine Hypoxanthine 0.185 1.20E-08
Xanthine N-[3-(2-oxopyrrolidin-1-yl)
propyl]acetamide
0.140 1.68E-05
Tyrosine 2-hydroxybutyrate -0.138 2.35E-05
Tyrosine 3-(4-hydroxyphenyl)lactate 0.319 1.37E-23
Tyrosine Caffeine 0.136 2.91E-05
Tyrosine Citrate -0.138 2.24E-05
Tyrosine Gamma-glutamyltyrosine 0.466 1.04E-51
Tyrosine Phenylalanine 0.201 5.44E-10
Tyrosine Tryptophan 0.268 7.02E-17
Dehydroepiandrosterone
sulfate
Epiandrosterone sulfate 0.299 8.64E-21
Dehydroepiandrosterone
sulfate
X-18601 0.574 3.66E-83
Dehydroepiandrosterone
sulfate
X-11315 0.141 1.47E-05
Dehydroepiandrosterone
sulfate
X-11443 -0.470 1.32E-52
Dehydroepiandrosterone
sulfate
X-11450 0.392 8.38E-36
Dehydroepiandrosterone
sulfate
X-12063 -0.193 2.51E-09
Dehydroepiandrosterone
sulfate
X-12844 0.138 2.10E-05
Epiandrosterone sulfate Androsterone sulfate 0.754 1.33E-172
Epiandrosterone sulfate X-11440 -0.178 3.93E-08
Epiandrosterone sulfate X-11443 0.411 1.48E-39
Epiandrosterone sulfate X-12844 0.161 6.94E-07
X-18601 Taurolithocholate 3-sulfate -0.134 4.04E-05
X-18601 X-12063 0.208 1.28E-10
X-18601 X-12844 -0.162 6.47E-07
X-11440 X-11445 0.314 7.74E-23
X-11440 X-11450 0.150 4.05E-06
X-11440 X-11470 0.140 1.75E-05
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estimation within these reduced sample sets. The male- and
female-specific partial correlation coefficients were com-
pared using a Fisher test (Levy and Narula 1978).
To compare the 58 edges within the generated urate
GGM, a Bonferroni corrected significance level of 0.05/
58 = 8.6 9 10-4 was applied. To test differences between
all possible pairs of 353 metabolites, a Bonferroni cor-
rected significance level of 0.05/62,128 = 8.0 9 10-7 was
applied.
3 Results and discussion
In a hypothesis-free approach, we generated a data-driven
GGM around serum urate, based on partial correlations.
Thereby, 38 metabolites were assigned to a network, con-
taining 26 known as well as 12 unknown metabolites
(Fig. 1). Table 1 shows the corresponding partial correla-
tion coefficients and p values for each of the edges within
the network. The general structure of the serum urate
network clusters into three parts of connected metabolites.
The first cluster contains mainly nucleotides, namely
xanthine, hypoxanthine, inosine, and uridine, as well as
arginine, and two unknown metabolites. It includes the
well-known pathway from inosine via hypoxanthine and
xanthine to urate. Xanthine is further connected to a cluster
of dipeptides, namely aspartyl-phenylalanine (aspartame),
leucylalanine, phenylalanylphenylalanine, and phenylala-
nylleucine and one unknown metabolite X-11805. The
conversion of hypoxanthine to xanthine and xanthine to
urate is catalyzed by the rate-limiting enzyme xanthine
oxidase, the only enzyme capable of catalyzing the for-
mation of urate in man (Pfeffer et al. 1994). The complex
mechanism by which xanthine oxidase catalyzes hypo-
xanthine and xanthine conversion has been described pre-
viously (Berry and Hare 2004; Hille and Massey 1981).
Xanthine oxidase is significantly elevated in a variety of
cardiovascular conditions such as coronary artery disease
and heart failure (George and Struthers 2009). There is a
large variability in human xanthine oxidase expression,
which can be up to three-fold and on average 20 % higher
in men than in women (Guerciolini et al. 1991). Although
basal expression of xanthine oxidase is low in humans,
hypoxias, IL-1, IL-6, TNF-a, lipo-polysaccharides as well
as steroid treatment have been shown to up-regulate tran-
scription (Berry and Hare 2004).
Aspartyl-phenylalanine (aspartame), a low-calorie
sweetener, is directly connected to xanthine in the network.
Aspartame was shown to pose antipyretic, analgesic and
anti-inflammatory action and to delay osteoarthritis in
animal models (LaBuda and Fuchs 2001; Manion et al.
2011; Pradhan et al. 2011). Interference of aspartame with
rheumatoid factor activity has been proposed to alleviate
the pain and immobility resulting from chronic inflamma-
tion of joints (Ramsland et al. 1999). Other (tryptophan-
containing) dipeptides were shown to inhibit xanthine
oxidase (Nongonierma and Fitzgerald 2012). The dipep-
tides connected to xanthine may therefore be interesting
Table 1 continued
Metabolite 1 Metabolite 2 Partial correlation
coefficient
p value
X-11440 X-12844 0.192 3.03E-09
X-11443 X-11450 0.213 4.88E-11
X-11443 X-12844 -0.155 2.00E-06
Aspartylphenylalanine X-11805 0.256 1.85E-15
Aspartylphenylalanine Leucylalanine 0.308 4.78E-22
Aspartylphenylalanine Phenylalanylleucine 0.393 5.02E-36
Aspartylphenylalanine Phenylalanylphenylalanine 0.155 1.94E-06
Hypoxanthine Arginine 0.137 2.45E-05
Hypoxanthine Inosine 0.254 3.05E-15
Hypoxanthine Uridine 0.152 2.80E-06
Hypoxanthine X-10810 0.162 6.03E-07
Hypoxanthine X-12442 -0.140 1.80E-05
3-(4-hydroxyphenyl)lactate Citrate 0.142 1.28E-05
X-11805 Phenylalanylleucine 0.142 1.36E-05
X-11805 Phenylalanylphenylalanine 0.342 4.55E-27
Leucylalanine Phenylalanylleucine -0.143 1.04E-05
Leucylalanine Phenylalanylphenylalanine -0.164 4.17E-07
Phenylalanylleucine Phenylalanylphenylalanine 0.155 1.86E-06
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targets for the identification of novel treatments or pre-
vention strategies for hyperuricemia and related diseases.
Urate and xanthine are further connected to N-[3-(2-
oxopyrrolidin-1-yl)propyl]acetamide (acisoga), a metabo-
lite of spermidine. Our metabolite network does not pro-
vide the first link between urate and spermidine.
Spermidine and spermine were previously found to bind
the organic anion transporter OAT1 in mice, and to be
putative novel endogenous substrates of OAT1 (Ahn et al.
2011), which is also known to be a urate transporter (Ichida
et al. 2003).
The second large cluster contains several essential
amino acids and is connected via methionine and histidine
to serum urate in our network. Histidine, tryptophan, and
tyrosine are amino acids which are especially sensitive to
hydroxyl radical exposure (Davies et al. 1987). Methionine
enriched diet is known to decrease urate levels in chickens
and ducks, whereas only a few small studies have analyzed
the effect in humans (Xie et al. 2004). Furthermore,
methionine can be demethylated to homocysteine and
elevated homocysteine levels have, as well as elevated
urate levels, been shown being a risk factor for athero-
sclerosis, coronary heart disease, and chronic kidney dis-
ease (Francis et al. 2004; Humphrey et al. 2008;
Lubomirova et al. 2007). Significant associations between
serum urate and homocysteine have been shown in plasma
and serum (Lussier-Cacan et al. 1996; Malinow et al.
1995).
Fig. 1 Serum urate GGM representing all significant associations
within a three-neighborhood of serum urate. The thickness of each
edge corresponds to the strength of partial correlation. Positive
associations are marked as black lines, whereas negative correlations
are represented by red lines. Metabolites are colored according to
their biological pathways
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The third cluster correlated with serum urate is com-
posed of steroids and several unknowns. The different
concentrations of serum urate in both sexes and the higher
incidence of gout in men compared to women, suggest a
hormonal influence on the pathogenesis of gout (Gregolini
et al. 1983). Excretion of urinary dehydroepiandrosterone
and androsterone has been reported to be significantly
lower in subjects with gout (Sparagana and Phillips 1972).
A small study investigating the hormonal urinary excretion
reported that patients previously treated with allopurinol
showed slightly higher values of androsterone and dehy-
droepiandrosterone, and slightly lower values of 11-hy-
droxyandrosterone in comparison to normal subjects,
suggesting different hormonal patterns between individuals
with and without gout (Gregolini et al. 1983).
For all metabolites within the network we tested the
influence of sex and urate lowering medication within a linear
model. Table 2 shows the corresponding effect estimates.
Table 2 Influence of sex and
urate lowering medication on
levels of all metabolites within
the 3-neighborhood of serum
urate
The linear model was
additionally adjusted for age
(effects not shown). Males are
coded 0, females are coded 1.
Medication intake was coded
with 1 compared to no
medication intake 0
Metabolite Beta
sex
p value
sex
Beta
medication
p value
medication
2-Hydroxybutyrate -0.108 1.16E-08 -0.169 1.75E-04
3-(4-Hydroxyphenyl)lactate -0.340 1.81E-90 -0.175 4.10E-06
Androstene disulfate -0.817 8.78E-103 -0.226 7.40E-03
Androsterone sulfate -0.360 7.86E-23 0.092 2.84E-01
Arginine 0.019 1.05E-01 0.056 4.03E-02
Aspartylphenylalanine -0.034 2.68E-01 -0.169 2.16E-02
Caffeine -0.074 1.28E-01 -0.605 2.17E-07
Citrate 0.029 2.14E-02 -0.055 7.26E-02
Dehydroepiandrosterone sulfate -0.436 1.85E-49 0.195 4.08E-03
Epiandrosterone sulfate -0.518 6.28E-59 0.141 5.36E-02
Gamma-glutamyltyrosine -0.091 2.71E-16 -0.076 3.53E-03
Histidine 0.032 5.29E-07 0.006 6.79E-01
Hypoxanthine 0.056 7.45E-05 -0.100 2.75E-03
Inosine 0.226 4.74E-09 0.034 7.12E-01
Leucylalanine 0.130 8.71E-08 0.117 4.12E-02
Methionine -0.110 3.91E-52 0.054 1.35E-03
N-[3-(2-oxopyrrolidin-1-yl)
propyl]acetamide
-0.026 1.11E-01 -0.275 3.46E-12
Phenylalanine -0.056 1.69E-19 -0.076 1.92E-07
Phenylalanylleucine -0.086 1.56E-03 -0.177 6.08E-03
Phenylalanylphenylalanine -0.004 8.67E-01 -0.107 4.43E-02
Taurolithocholate 3-sulfate -0.002 9.61E-01 -0.249 2.94E-03
Tryptophan -0.080 2.99E-32 -0.036 2.16E-02
Tyrosine -0.060 3.37E-12 -0.041 4.07E-02
Urate -0.206 1.20E-112 0.027 1.78E-01
Uridine 0.009 3.42E-01 0.054 1.95E-02
Xanthine 0.059 3.66E-06 -0.896 7.08E-157
X-10810 -0.061 3.60E-03 0.058 2.43E-01
X-11315 0.151 1.40E-13 0.048 3.17E-01
X-11440 -0.600 3.04E-90 -0.069 3.03E-01
X-11443 -1.247 8.12E-196 -0.166 5.58E-02
X-11445 -0.081 1.32E-02 0.019 8.09E-01
X-11450 -0.512 1.61E-88 -0.049 3.97E-01
X-11470 -0.158 1.33E-17 0.102 1.94E-02
X-11805 -0.044 1.92E-01 -0.363 6.51E-06
X-12063 -0.207 1.14E-12 -0.207 2.69E-03
X-12442 0.126 8.04E-08 -0.093 9.24E-02
X-12844 0.030 1.01E-01 0.087 4.39E-02
X-18601 -0.550 2.13E-71 0.134 5.55E-02
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25 of the 38 metabolites show strong differences between men
and women (7.5 9 10-5 C p C 8.1 9 10-196). These large
differences are in line with our previous work on sexual
dimorphisms revealing significant concentration differences
between males and females for 102 out of 131 metabolites
(Mittelstrass et al. 2011).
While the metabolites within the network expectedly
show strong sex differences, we observe that the network
itself is not sensitive to sex differences. To address this we
compared all partial correlations within the network
between men and women (Supplementary Table 2). Only
eight of the 58 edges show a significant difference between
men and women at a significance level of 8.6 9 10-4.
Furthermore, we compared all pairwise partial correlations
within the whole dataset of 353 metabolites. This global
comparison shows that there are three edges below the
significance level of 8.0 9 10-7 proving that there are no
strong sex differences, which means that the network itself
is not sex dependent.
Seven of the metabolites show a significant influence of
urate lowering medication. The strongest influence of medi-
cation intake is seen for xanthine (p = 7.1 9 10-157). Fur-
thermore, medication shows a significant influence on
phenylalanine (p = 1.9 9 10-7), caffeine (p = 2.2 9
10-7), 3-(4-hydroxyphenyl)lactate (p = 4.1 9 10-6),
2-hydroxybutyrate (p = 1.7 9 10-4), N-[3-(2-oxopyrroli-
din-1-yl)propyl]acetamide (p = 3.5 9 10-12), and X-11805
(p = 6.5 9 10-6). Allopurinol intake inhibits the enzyme
xanthine oxidase which is responsible for the successive
oxidation of hypoxanthine to xanthine and xanthine to urate.
Figure 2 visualizes the medication and sex effects for urate,
xanthine, and hypoxanthine. Urate levels themselves do not
show differences between medicated and medication-free
individuals (p = 0.18) and also for hypoxanthine the influ-
ence of medication is much weaker than on xanthine and not
significant after correcting for multiple testing (p = 2.7 9
10-3). While the strong association between allopurinol
intake and xanthine was expected, we additionally observed a
medication influence on several amino acids, one unknown
metabolite, and caffeine. Previous epidemiological studies
found that coffee consumption is inversely associated with
serum urate levels (Choi and Curhan 2007) and an influence of
allopurinol medication on caffeine has been described (Birkett
et al. 1997; Fuchs et al. 1999). Data on nutrition was not
available, therefore we cannot exclude the possibility that the
observed associations might be confounded by diet factors
especially by those typically recommended for patients with
gout.
4 Concluding remarks
Metabolomic research has been expanded to epidemio-
logical studies with the advent of new high-throughput
technologies. Because of their immediacy to cell physiol-
ogy, the measurement of metabolites provides a promising
technique to discover new disease markers and pathways.
We have generated a data-driven metabolite network
around serum urate based on metabolite profiling of 1,764
individuals of the KORA F4 survey, to reconstruct path-
ways of biochemically related metabolites in a hypothesis-
free approach.
We linked the regulation of serum urate to three dif-
ferent clusters of metabolites: While the connection to
purine metabolism is well known, our current approach
also links it to several essential amino acids and steroid
hormones. We see sex differences for 25 of the 38
metabolites within the network. Furthermore, metabolites
showed a dependency on uricostatic medication. Our
findings may advert to new regulatory pathways and
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Fig. 2 Levels of urate, xanthine, and hypoxanthine stratified between
females and males as well as stratified between M = medication-free
and M = medicated individuals. Medication-free females: n = 891,
medicated females: n = 17, medication-free males: n = 790, and
medicated males: n = 66)
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molecular mechanisms. This opens up new avenues for the
identification of novel treatment targets and the prevention
of hyperuricemia and related diseases as gout, cardiovas-
cular disease and type 2 diabetes.
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